a andastan aw i go bi hevi en frayd we dem no se yu geht breast cancer. Na wan say, di wɔri de bɔt di sik, ɛn na di ɔda say, we dɔktɔ dɛn se wɔd dɛn lɛk ``(Kɛmotɛrapi)`` ɛn ɔmon tɛrapi , yu maynd kin kɔnfyus mɔ, nɔto so? "A go gɛt kemo bak? Mi ia go fɔdɔm? I go at fɔ mi bɔdi?" Yu go mɔs gɛt bɔku kwɛstyɔn dɛn na yu maynd. Bɔt nɔ wɔri. Tide, wi go tɔk bɔt aw yu ej ɛn if yu dɔn go tru menopause ɔ nɔ go bi impɔtant fɔ no di tritmɛnt we dɛn go gi yu.
Trade, klos to ɔlman bin de gi kemotɛrapi jɔs afta dɛn kam fɔ no se bɔdi kansa dɔn go na di limf no dɛm. I bin tan lɛk se yu ol hama ɛn mek ɔltin tan lɛk nel. Bɔt naw mɛrɛsin dɔn go bifo bɔku. Naw wi no se nɔto ɔl di bɔdi kansa na di sem, ɛn nɔto ɔl di wan dɛn we sik go du di sem tritmɛnt. Sɔntɛnde, di bad tin dɛn we kin apin we pɔsin tek kimotɛrapi kin pas di bɛnifit dɛn we pɔsin kin gɛt. So naw dɔktɔ dɛn nɔ jɔs bisin bɔt di sayz fɔ di tumbu ɛn di stej we di kansa de, bɔt dɛn de bisin bak bɔt di bayolojikal we aw di kansa de.
Wetin mek fɔ lɛf fɔ gɛt bɛlɛ impɔtant to dis stori?
If yu dɔn go tru ɔ nɔr dɔn go tru menopause, di tɛm we yu prɛgnɛshɔn kin stɔp fɔ ɔltɛm, rili impɔtant fɔ trit yu bɔdi kansa. Bɔku rizin dɛn de fɔ dis.
Fɔ tɔk am simpul wan, di bɔdi kansa pan uman dɛn we yɔŋ, we nɔ rich 18 ia yet, kin gɛt smɔl mɔ agresiv pas kansa pan uman dɛn we dɔn pas 40 ia .
Apat frɔm dat, i de sho bak di kayn tritmɛnt we yu go gɛt. Fɔ ɛgzampul, if yu gɛt kansa we de dipen pan ɔmon, di kayn ɔmon tritmɛnt we yu go gɛt go difrɛn difrɛn wan bay aw yu dɔn lɛf fɔ gɛt bɛlɛ.
- Postmenopausal: Dɛn kin gi yu mɛrɛsin lɛk Arimidex, we de stɔp di bɔdi fɔ mek di ɔmon we dɛn kɔl ɛstrojen.
- If yu de bifo yu dɔn pas 40 ia: Yu ovaria dɛn stil de mek ɛstrojen, so mɛrɛsin dɛn lɛk Arimidex nɔ go rili wok. So bɔku tɛm yu dɔktɔ go gi yu wan mɛrɛsin we dɛn kɔl Tamoxifen. Dis de wok bay we i de blok di mɛsej we ɛstrojen de sɛn to di kansa sɛl dɛn.
Yu ɔndastand? Dipen pan aw yu bɔdi in ɔmon dɛn de chenj, di mɛrɛsin dɛn we de fɛt kansa fɔ chenj bak.
Bayoloji fכ Kεnsar: Hכmon Risεptor dεm εn HER2
Okay, naw mek wi dig dip smɔl. If yu lɛf asay if ɔmon tɛrapi fayn fɔ yu ɔ nɔ rayt fɔ yu, di nɛks big kwɛstyɔn na if yu nid kemotɛrapi ɔ nɔ nid am.
Bɔku tɛm dis kin bi bay di kayn tin dɛn we de na di say we yu kansa sɛl dɛn de . Tink bɔt dɛn riseptɔ ya as di ‘antena’ dɛn we de pan di kansa sɛl dɛn. dis antena dεm de pik di ‘signal’ dεm we di kεnsar nid fכ gro. tu men kayn rεsεpכta dεm de we wi de luk pan.
1. di כmon rεsεpכta dεm (HR): di rεsεpכta dεm we de sεnsitiv to di כmon dεm we dεn kכl εstrojen εn projεstεron.
2. HER2 rεsεpכta: dis na כda protin we de εp di kεnsar sεl dεm fכ gro.
Si di tebul dɔŋ ya fɔ aw dɛn kin klas kansa ɛn no aw fɔ trit dɛn bay di kɔmbaynshɔn fɔ dɛn wan ya.
| Di kayn kansa (dipen pan di ansa) . | Minin ɛn jenɛral tritmɛnt plan |
|---|---|
| HR-positiv, HER2-nεgεtiv | Ɔmon-sɛnsitiv, bɔt HER2-insɛnsitiv. Ɔmon tɛrapi kin wok fayn. Fɔ disayd if dɛn nid fɔ tek kemotɛrapi ɔ nɔ nid fɔ tek am, na tin we at fɔ du. Menopausal stetus rili impɔtant ya. |
| HR-positiv, HER2-positiv | Sεnsitiv to כl tu di כmon dεm εn HER2. Wan kɔmbaynshɔn fɔ ɔmon tɛrapi ɛn HER2-target tɛrapi kin gi gud rizɔlt. Bɔku tɛm, dɛn kin avɔyd fɔ tek bad bad kemotɛrapi. |
| HR-nεgεtiv, HER2-pכzitiv | Nɔto sɛnsitiv to ɔmon, bɔt i de sɛnsitiv to HER2. Kimotɛrapi nid fɔ de wit HER2-targeted tɛrapi. |
| Tripul-Nɛgitiv | כl tu di כmon rεsεpכta dεm εn di HER2 rεsεpכta dεm nכ de, כl tri. So, nɔto ɔmon tɛrapi ɔ HER2-target tɛrapi nɔ de wok. Bɔku tɛm, i rili nid fɔ tek kimotɛrapi. |
Wetin na di Oncotype Dx tɛst?
If yu kansa na HR-positiv, HER2-negative, dat na, di fɔs kayn na di tebul we de ɔp, di kwɛstyɔn "A nid kemo?" na di wan we at fɔ ansa. na insay kes dεm lεk dis we dכkta dεn de yuz jεnomik tεst lεk `Oncotype Dx` .
Dis tɛst de analayz 21 jin dɛn na wan smɔl sampul fɔ yu kansa. Bay dis, i de gi yu wan mak we de sho if yu kansa gɛt smɔl, mɔdaret, ɔ ay risk fɔ kam bak tumara bambay.
- Low score: Bɔku tɛm yu kin wɛl if yu nɔ gɛt kemotɛrapi .
- If di mak ay: Na di bɛst we fɔ tek kimotɛrapi.
Bɔt bɔku pipul dɛn kin gɛt intamɛdiet mak . Na de di prɔblɛm kin kam bak.
Ansa dɛn frɔm nyu risach
Laki se tu big stɔdi dɛn we dɛn jɔs du, TAILORx ɛn RxPONDER, dɔn gi rili gud ansa to di kwɛshɔn bɔt wetin fɔ du wit dɛn uman ya we gɛt mɔdaret skɔ. Dɛn stɔdi ya dɔn sho mɔ se i impɔtant fɔ lɛ pɔsin nɔ gɛt bɛlɛ.
- TAILORx trial (fɔ pipul dɛm wae dɛn kansa nɔr dɔn spre to limf no dɛm):
- Dis stכdi sho klia wan se uman dεm we dεn pas mεnopos wit mכdarεt Oncotype Dx skכ dεm nכ de gεt εni כda bεnεfit frכm kεmothεrapi. Ɔmon tritmɛnt nɔmɔ go du fɔ dɛn.
- RxPONDER stכdi (fכ pipul dεm we gεt kεnsar we dεn spre to di limf no dεm):
- Dis de sho bak di sem tin. Bɔku pan di uman dɛn we dɔn pas 40 ia , ilɛksɛf di kansa dɔn skata to di limf no dɛm, nɔ kin bɛnifit bɛtɛ frɔm kemotɛrapi.
- Bɔt di stori difrɛn atɔl fɔ uman dɛn we nɔ rich 18 ia yet, mɔ di wan dɛn we nɔ rich 50 ia yet. We dɛn ad kemotɛrapi to ɔmon tɛrapi fɔ dɛn, di ebul fɔ mek kansa nɔ kam bak kin bɔku .
Fɔ tɔk am simpul wan, if yu na yɔŋ uman we nɔ rich 18 ia yet, kemotɛrapi kin bi pawaful wɛpɔn we go sev yu layf. Bɔt if yu dɔn pas we yu dɔn pas 40 ia, yu kin ebul fɔ gɛt bɛtɛ rizɔlt wit ɔmon tɛrapi we yu nɔ go gɛt di bad tin dɛn we i kin du.
Faynal disizhɔn ɛn tin dɛn we yu fɔ tink bɔt
Wit ɔl dis, yu go dɔn ɔndastand aw i nɔ izi fɔ mek yu wangren disayd fɔ du dɛn tin ya. Na dat mek i rili impɔtant fɔ tɔk opin wan bɔt ɔl dis wit yu dɔktɔ.
If yu dɔn pas we yu dɔn pas 40 ia, ɔda tin de we yu fɔ mɛmba. Kimotɛrapi kin mek yu prɛgnɛshɔn stɔp fɔ ɔltɛm ɛn mek yu menɔpauz kwik kwik wan. Fɔ di wan dɛn we yɔŋ, yu prɛgnɛshɔn kin stɔp fɔ sɔm tɛm ɛn bigin bak. Bɔt if yu op fɔ bɔn pikin tumara bambay, mek shɔ se yu tɔk to yu dɔktɔ bɔt aw fɔ mek yu nɔ bɔn pikin bifo yu bigin fɔ trit yu.
As tɛm de go, yu ɛn yu dɔktɔ go disayd us tritmɛnt go fayn fɔ yu. Insay da tɔk de, yu kayn kansa, di stej we yu gɛt, di Oncotype Dx skɔ, ɛn if yu dɔn pas we yu dɔn pas 40 ia, na ɔl di impɔtant tɔpik dɛn fɔ tɔk bɔt.
Mɛsej we dɛn kin kɛr go na os
- Nɔto ɔl di bɔdi kansa na di sem, so di sem tritmɛnt nɔ fayn fɔ ɔlman.
- Ilɛksɛf yu dɔn go tru mɛnɔpauz ɔ yu nɔ go pas, dat go rili afɛkt di tritmɛnt we yu go gɛt, mɔ di kemotɛrapi ɛn ɔmon tɛrapi.
- Jεnεtik tεst lεk Oncotype Dx kin εp uman dεm we gεt HR-positiv, HER2-negative kεnsar fכ no if kεmothεrapi nid fכ de.
- Risach we dɛn dɔn du dis biɛn tɛm sho se bɔku tɛm, uman dɛn we dɔn pas 18 ia nɔ kin gɛt ɛni ɔda bɛnifit frɔm kemotɛrapi, bɔt i kin rili bɛnifit uman dɛn we dɔn pas 18 ia.
- Bi opin ɛn ɔnɛs to yu dɔktɔ bɔt yu tritmɛnt plan. Tɔk klia wan bɔt yu ej, di we aw yu dɔn lɛf fɔ gɛt bɛlɛ, ɛn di tin dɛn we yu dɔn plan fɔ du tumara bambay (lɛk fɔ bɔn pikin).
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt